Your partner in oncology


Oncology Therapeutic Development

100 rue Martre
92110 Clichy - FRANCE
Tel:  +33 1 47 15 01 01
Fax: +33 1 45 19 06 59

Contact Us

About us

Founded in 2005 by Prof. Esteban Cvitkovic, Oncology Therapeutic Development (OTD) is a Paris-based boutique CRO spin-off from a former oncology-specialist CRO. The two major axes of our small and highly experienced team overseen by Prof. Cvitkovic, are the Clinical and Consulting groups, with an infrastructure of medical oncologists, project managers, and CRAs, supported by medical writing and admin staff. The team collaborates actively with data management, statistics, and PK/PD groups, as well as regulatory experts. Our strength lies in our diverse backgrounds, extensive oncology experience and high-level training. 


Management Team

Esteban CVITKOVIC, MD, OTD Founder and Head Consultant

A medical oncologist specialized in solid tumors and drug development, Prof. Cvitkovic has been instrumental in defining the clinical utility of several oncology drugs contributing to their registration, including cisplatin, oxaliplatin, vinorelbine, irinotecan, docetaxel and trabectedin. He was responsible for leading therapeutic advances in germ cell tumors, squamous head and neck cancer, EBV-related nasopharyngeal carcinoma, soft tissue sarcomas and gastrointestinal cancers.

Prof. Cvitkovic has nearly 50 years of international experience in oncology therapeutics, including hands-on clinical research and pharmacology, disease-oriented therapeutic impact assessment, developing new regimens, evaluating novel agents in preclinical development and optimizing clinical efficacy. He graduated in Argentina as the world's youngest MD at the age of 19, and has held staff and academic appointments at Memorial Sloan Kettering and Columbia Presbyterian (New York, US), Instituto Mario Negri (Milan, Italy), Gustave Roussy, Hôpital Paul Brousse and Hôpital Saint-Louis (France). He has authored more than 250 peer-reviewed articles. 

Career highlights include founding the oncology-focused CRO Cvitovic & Associés Consultants (CAC) in 1996 which was sold to AAIPharma in 2006, and co-founding OncoEthix, a biotechnology company focused on the early development of the first bromodomain inhibitor, sold to Merck in 2014.

Mohamed BEKRADDA, MD, Senior Medical Director

Dr. Bekradda is a board-certified medical oncologist with nearly 30 years of experience in Phase I-III clinical development of anticancer drugs. His focus has been on genitourinary and gastrointestinal cancers. Highlights include therapeutic evaluation in hormone-resistant prostate cancer, development of cisplatin chemotherapy regimens for non-seminomatous germ cell tumors and oxaliplatin regimens of colorectal cancer and NSCLC He has worked with a range of agents, including docetaxel, oxaliplatin, alemtuzumab, capecitabine, trastuzumab and advexin. He has also led onsite reviews for large international compassionate-use cohorts.

Dr. Bekradda has held academic and staff appointments in France at Gustave Roussy), Centre Léon Bérard and the Center Hospitalier Sud Francilien. In 1996, he cofounded CAC with Prof. Cvitkovic. Prior to joining OTD, Dr. Bekradda worked at Hoffmann-La Roche Ltd.

Fabrice BOURDEL, MScSenior Project Manager

Fabrice has an MSc in cellular and molecular biology. He has nearly 20 years experience in clinical oncology research working at the oncology-specialized CRO CAC and subsequently with AAIPharma, managing more than 20 Phase I/II clinical trials. His particular expertise lies in phase I/II oncology trial, including first-in-human agents. He also has EMA pharmacovigilance certification.

Sarah MACKENZIE, PhDMedical Writing Manager

Sarah has a PhD in developmental biology and nearly 20 years experience in early clinical oncology with big pharma and small biotech clients while working with CAC and AAIPharma prior to joining OTD. Her experience covers regulatory clinical documents (protocols, CSRs, SAE narratives, investigator brochures, clinical summaries), preclinical reports, and peer-reviewed manuscripts, posters and abstracts.